La Jolla Pharmaceutical Company Announces Filing of Joint Proxy Statement/Prospectus |  |
|
Posted by BioSpace.com Featured News December 22nd, 2009 .
| |
| No Comments |
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (La Jolla) today announced that it has filed its Registration Statement on Form S-4 with the Securities and Exchange Commission (SEC) in connection with its proposed merger with Adamis Pharmaceuticals Corporation (Adamis). The definitive merger agreement was entered into on December 4, 2009 and closing of the merger is...
See other entries categorized in BioSpace, News, Syndication.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
